The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of Xanax (alprazolam) due to failed dissolution specifications. The recall, initiated by pharmaceutical company Viatris Inc., affects 3mg extended-release tablets sold in 60-tablet bottles.
Immediate Action & Core Facts
The FDA classified the recall as Class II, indicating a moderate risk where the affected pills could cause temporary or reversible adverse health effects. The recall applies to lot number 8177156, with an expiration date of February 28, 2027. The affected pills were distributed between August 27, 2024, and May 29, 2025.
Deeper Dive & Context
Recall Details
The recall stems from concerns that the medication may not dissolve properly in the body, potentially reducing its effectiveness. The FDA emphasizes that no adverse reactions have been reported so far. Patients with the affected lot are advised to stop taking the medication immediately.
Public Health Impact
An estimated 3.6 million people in the U.S. receive prescriptions for Xanax annually. The drug, a benzodiazepine, is commonly prescribed to treat anxiety disorders by slowing down the brain and nervous system.
Regulatory Response
The California State Board of Pharmacy has urged pharmacies to review their quality assurance policies in response to the recall. Viatris has not issued a public statement regarding the recall as of the latest reports.
Patient Guidance
Patients with the recalled lot should consult their healthcare providers for alternative treatment options. The FDA and Viatris have not provided further updates on the recall's scope or timeline.